Ultravist 370

  • Imaging agents

Ultravist 370 Generic Name & Formulations

General Description

Iopromide 768.86mg (equivalent to 370mg of iodine) per mL; soln; preservative-free; contains tromethamine and edetate calcium disodium.

How Supplied

Single-dose vials (50mL, 100mL, 125mL, 150mL)—10


Mechanism of Action

Iopromide is a nonionic, water soluble, tri-iodinated x-ray contrast agent for intravascular administration. Intravascular injection of iopromide opacifies those vessels in the path of flow of the contrast agent, permitting radiographic visualization of the internal structures until significant hemodilution occurs.

Ultravist 370 Indications


Intra-arterial: Coronary arteriography and left ventriculography, visceral angiography and aortography. IV: CT imaging of head and body (intrathoracic, intra-abdominal and retroperitoneal regions) for the evaluation of neoplastic and non-neoplastic lesions. 

Ultravist 370 Dosage and Administration


Intra-arterial (Coronary arteriography and left ventriculography): Right/left coronary artery: 3–14mL; Left ventricle: 30–60mL; max 225mL. IV: CT of head: 41–162mL; CT of body (single phase contrast): 41–162mL bolus inj or 81–162mL rapid infusion; max 162mL (60g iodine). IV: CT of body (multiple phase contrast): 41–162mL total volume; Phase 1: 100% contrast; Phase 2: 20–60% contrast using a power injector suitable for simultaneous inj of contrast and saline; max 162mL (60g iodine). Renal impairment: use lowest necessary dose.


<2yrs: not established. ≥2yrs: Intra-arterial: Cardiac chambers and related arteries: 1–2mL/kg; max 4mL/kg. Renal impairment: use lowest necessary dose.

Ultravist 370 Contraindications


Intrathecal use. Preparatory dehydration in children.

Ultravist 370 Boxed Warnings

Boxed Warning

Not for intrathecal use.

Ultravist 370 Warnings/Precautions


Do not administer intrathecally: severe reactions may occur (eg, death, convulsions/seizures, cerebral hemorrhage, coma, paralysis, arachnoiditis, acute renal failure, cardiac arrest, rhabdomyolysis, hyperthermia, brain edema). Have resuscitation equipment and trained personnel available for at least 30–60min after administration. Contrast induced acute kidney injury may occur; risk factors include pre-existing renal insufficiency, diabetes, dehydration, CHF, advanced vascular disease, elderly, multiple myeloma/paraproteinemia). Ensure adequate hydration. Cardiovascular disease (monitor). Monitor ECGs and vital signs. Thromboembolic complications. Homocystinuria: avoid angiocardiography. Hyperthyroidism. Thyroid dysfunction (esp. children 0–3yrs); monitor. Pheochromocytoma. Homozygous sickle cell disease. Avoid extravasation (esp. in arterial or venous disease). History of severe cutaneous reaction: avoid. Children: asthma, cyanotic and acyanotic heart disease, CHF, serum creatinine >1.5mg/dL, immature renal function, dehydration: increased risk of adverse effects. Elderly. Pregnancy. Nursing mothers: may consider interrupting breastfeeding for 12–24hrs after administration.

Ultravist 370 Pharmacokinetics


  • Steady-state volume of distribution: 16 L.

  • 1% plasma protein bound.


  • Renal (97%), fecal (2%)

  • Mean total renal clearance: 107mL/min.

Ultravist 370 Interactions


Increased risk for contrast induced acute kidney injury with nephrotoxic or diuretic drugs. May increase risk of metformin-induced lactic acidosis. Caution with concomitant beta-blockers. Recently received cholecystographic agents in patients with hepatic or biliary disorder; increased risk of renal toxicity. Do not mix with other drugs. Radioactive iodine uptake studies may not accurately reflect thyroid function for at least 16 days. May affect coagulation parameters (increased thrombin time, PTT, thrombin coagulase time).

Ultravist 370 Adverse Reactions

Adverse Reactions

Headache, nausea, injection site and infusion site reactions, vasodilatation, vomiting, back pain, urinary urgency, chest pain, pain, dysgeusia, abnormal vision; anaphylactoid reactions, acute kidney injury, cardiovascular reactions.

Ultravist 370 Clinical Trials

See Literature

Ultravist 370 Note

Not Applicable

Ultravist 370 Patient Counseling

See Literature